AbbVie Inc. (NEO:ABBV)

Canada flag Canada · Delayed Price · Currency is CAD
24.85
+0.28 (1.14%)
Apr 17, 2025, 4:00 PM EDT
1.22%
Market Cap 434.42B
Revenue (ttm) 81.06B
Net Income (ttm) 6.10B
Shares Out n/a
EPS (ttm) 3.44
PE Ratio 71.24
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,658
Average Volume 10,726,593
Open 24.83
Previous Close 24.57
Day's Range 24.82 - 25.12
52-Week Range 22.44 - 31.45
Beta 0.54
RSI 36.95
Earnings Date Apr 25, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]

Sector Healthcare
Founded 2012
Employees 55,000
Stock Exchange Cboe Canada
Ticker Symbol ABBV
Full Company Profile

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD Financial Statements

News

There is no news available yet.